
Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other EventsItem 8.01. Other Events.
On October16, 2018, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing its next central nervous system product candidate, AXS-12 (reboxetine), which the Company is developing for the treatment of narcolepsy.
The full text of the press release is filed as Exhibit99.1 hereto, and is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits.
Exhibit Number |
Description |
99.1 |
Press release dated October16, 2018. |